Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06906380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: May 7, 2025 to Mar 15, 2026
    • Study sites: 0 to 3
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the long-term safety of ARD103 cellular therapies
Trial Details
NCT Number NCT06906380
Lead Sponsor ARCE Therapeutics, Inc.
Conditions
(from sponsor)		 Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
Related terms Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute
Enrollment 49 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov